Efficacy and safety of selective cyclin-dependent kinases 4/6 inhibitors in hormone-receptor-positive, HER2-negative advanced breast cancer – results from a real-world setting

Background: Selective cyclin-dependent kinases 4/6 inhibitors (CDKi) have become the standard of care in patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer (ABC). We performed retrospective analysis in patients treated with CDKi in the first year of their routine clin...

ver descrição completa

Detalhes bibliográficos

Principais autores:	ANJA KOVAČ, Erika Matos, Cvetka Grašič Kuhar, Marina Čakš, Tanja Ovčariček, Marina Mencinger, Mojca Humar, Simona Borštnar
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2020-01-01
coleção:	Cancer Treatment and Research Communications
Assuntos:	Hr-positive Her2-negative advanced breast cancer Cyclin-dependent kinases 4/6 inhibitors Real-world evidence Time-to-treatment failure Overall survival
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2468294220300381
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!